FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:2186-2188 December 4, 2003 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Huskamp, H. A. PubMed Citation

While much of the nation has been following the deliberations in Congress over a Medicare drug benefit, a quiet revolution has been taking place in the way benefits are managed for the 200 million Americans who already have insurance for prescription drugs. Just 10 years ago, most insured persons were required to make a standard copayment of $5 or less for a prescription, regardless of the type of medication they purchased. Now, incentive-based formularies are standard, with the amount of copayments depending on the type of drug prescribed; the contracts among the insurer, the manufacturer, and the pharmacy; and the . . . [Full Text of this Article]

Source Information

From the Heller School for Social Policy and Management, Brandeis University, Waltham, Mass.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.